- Home
- GOSS vs EFR Comparison
GOSS vs EFR Comparison
Compare GOSS & EFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- EFR
- Stock Information
- Founded
- GOSS 2015
- EFR 2003
- Country
- GOSS United States
- EFR United States
- Employees
- GOSS N/A
- EFR N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- EFR Trusts Except Educational Religious and Charitable
- Sector
- GOSS Health Care
- EFR Finance
- Exchange
- GOSS Nasdaq
- EFR Nasdaq
- Market Cap
- GOSS 347.8M
- EFR 344.0M
- IPO Year
- GOSS 2019
- EFR N/A
- Fundamental
- Price
- GOSS $2.47
- EFR $11.71
- Analyst Decision
- GOSS Strong Buy
- EFR
- Analyst Count
- GOSS 4
- EFR 0
- Target Price
- GOSS $8.50
- EFR N/A
- AVG Volume (30 Days)
- GOSS 3.1M
- EFR 88.6K
- Earning Date
- GOSS 08-05-2025
- EFR 01-01-0001
- Dividend Yield
- GOSS N/A
- EFR 9.43%
- EPS Growth
- GOSS N/A
- EFR N/A
- EPS
- GOSS N/A
- EFR 1.69
- Revenue
- GOSS $40,237,000.00
- EFR N/A
- Revenue This Year
- GOSS N/A
- EFR N/A
- Revenue Next Year
- GOSS $30.65
- EFR N/A
- P/E Ratio
- GOSS N/A
- EFR $7.74
- Revenue Growth
- GOSS N/A
- EFR N/A
- 52 Week Low
- GOSS $0.66
- EFR $10.95
- 52 Week High
- GOSS $2.65
- EFR $13.29
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- EFR 43.60
- Support Level
- GOSS $2.38
- EFR $11.64
- Resistance Level
- GOSS $2.65
- EFR $11.79
- Average True Range (ATR)
- GOSS 0.15
- EFR 0.09
- MACD
- GOSS 0.03
- EFR 0.01
- Stochastic Oscillator
- GOSS 76.67
- EFR 60.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About EFR Eaton Vance Senior Floating-Rate Fund of Beneficial Interest
Eaton Vance Senior Floating Rate Trust is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income. As a secondary objective, the fund intends to seek capital preservation. Its portfolio of investments consists of Software, Health Care Providers & Services, Machinery, Chemicals, Professional Services, IT Services, Hotels, Restaurants & Leisure, Capital Markets, Specialty Retail, Commercial Services & Supplies, and other areas. The trust invests in below investment grade floating rate loans, which are considered speculative because of the credit risk of their issuers.